Hay | Jotup

Laura Hay Named to MetLife’s Board of Directors

Retrieved on:

Wednesday, February 28, 2024

MetLife, Inc. (NYSE: MET) today announced that Laura Hay has been elected to its board of directors, effective immediately.

Key Points:

MetLife, Inc. (NYSE: MET) today announced that Laura Hay has been elected to its board of directors, effective immediately.
View the full release here: https://www.businesswire.com/news/home/20240227857191/en/
LAURA HAY NAMED TO METLIFE’S BOARD OF DIRECTORS (Photo: Business Wire)
Hay was Global Head of Insurance at KPMG LLP prior to her retirement in 2023, where she was an advisor on transformation, growth strategy, customer-focused innovation and risk mitigation to global boards and executive management teams.
Hay was a member of the KPMG Global Financial Services Leadership Team and served on KPMG’s U.S. board of directors for five years and the KPMG Americas board for three years.
Hay was named an “Inspiring Woman in Finance” in 2022 by the CPCU Society.

Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma

Retrieved on:

Monday, January 22, 2024

Drug, Bile, Patient, MRD, Cancer, Neoplasm, MD, DNA, Hepatocellular carcinoma, Pancreatic cancer, DGX, Cholangiocarcinoma, Liver cancer, Hay, Quest Diagnostics, TLR9, Liver, Medical imaging

"Haystack MRD's sensitivity enables clinical investigators to closely follow molecular response and measure early evidence of treatment efficacy.

Key Points:

"Haystack MRD's sensitivity enables clinical investigators to closely follow molecular response and measure early evidence of treatment efficacy.
Intrahepatic cholangiocarcinoma is cancer that occurs in the parts of the bile ducts that are within the liver.
"A significant challenge in the development of immunotherapies for liver and pancreatic tumors is early measurement of response to treatment.
"We are thrilled to work with Haystack in pursuit of our mission to develop better therapeutic options for patients with liver and pancreatic tumors."

Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing

Retrieved on:

Tuesday, January 9, 2024

Ultima recently unveiled its platform technology, a new sequencing architecture that supports sequencing an entire genome for $100.

Key Points:

Ultima recently unveiled its platform technology, a new sequencing architecture that supports sequencing an entire genome for $100.
The collaboration will leverage Quest's expertise and scale in oncology, genomics and pathology and national scale in tumor biopsy and blood specimen collection.
“Ultima’s technology was designed for applications requiring greater sequencing depth, breadth, or frequency and both MRD testing and whole genome sequencing are premier examples of these.
As a result, whole genome sequencing is typically used for rare disease and some oncology testing, but less available for applications targeting large populations.

Nauticus Robotics Secures Additional Funding, Appoints New Executive Management, Improves Operations and Cost Structures, and Engages Strategic Advisor

Retrieved on:

Wednesday, January 10, 2024

General counsel, Depth, CFO, Halliburton, Robotics, Software, M&A, Hay, Intellectual property, Weatherford International, Merlot, Certification, Management

Nauticus anticipates executing a second tranche of investment, discussions for which are ongoing and aimed at providing funding for the year.

Key Points:

Nauticus anticipates executing a second tranche of investment, discussions for which are ongoing and aimed at providing funding for the year.
This includes the engagement of a new executive management team, culminating in the promotion of John W. Gibson, Jr. to interim CEO on January 4, 2024.
He has served as the President of Nauticus since last October and on the Board of Directors since 2022.
JD Yamokoski, the Company's long-time Chief Technology Officer, remains with Nauticus and rounds out the executive management team.

Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC

Retrieved on:

Monday, January 8, 2024

Roche, Lung cancer, DGX, Neoplasm, MRD, Research, Doctor of Philosophy, AFT, Chemoradiotherapy, Genentech, Quest Diagnostics, Patient, Safety, NSCLC, Hay, Pharmaceutical industry

BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT's interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable stage III non-small cell lung cancer (NSCLC).

Key Points:

BALTIMORE, Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Alliance Foundation Trials, LLC (AFT) for research use of Haystack Oncology's personalized MRD technology (Haystack MRD™) to analyze therapeutic response and provide molecular insights for AFT's interventional, randomized phase II clinical trial (AFT-57) in patients with unresectable stage III non-small cell lung cancer (NSCLC).
The AFT-57 clinical study is supported by Genentech, a member of the Roche Group, and will explore the efficacy and safety of an anti-PD-L1 atezolizumab (Tecentriq®) with or without tiragolumab (anti-TIGIT) in conjunction with chemoradiotherapy.
"Haystack MRD was purpose-built to detect ctDNA with unparalleled sensitivity, making it well-positioned to support the innovation of new treatment regimens."
"AFT is excited to work with Haystack Oncology to investigate promising new immunotherapy-based treatments in nationwide randomized cancer clinical trials," said David Kozono, MD, PhD, AFT Executive Officer and Alliance Immuno-Oncology Committee Co-Chair.

KeyBank announces Foundation grants in Hudson Valley and Metro New York

Retrieved on:

Friday, December 15, 2023

TARRYTOWN, N.Y., Dec. 15, 2023 /PRNewswire/ -- KeyBank announces twenty (20) charitable donations made by KeyBank Foundation, the bank's charitable foundation to nonprofit organizations throughout its Hudson Valley/Metro New York market. The gifts focus support to address homelessness, financial literacy, education, workforce development, minority small business development, and more. The charitable donations total $385,000 and are part of KeyBank's community philanthropic efforts targeted toward education, workforce development, and safe, vital neighborhoods.

Key Points:

TARRYTOWN, N.Y., Dec. 15, 2023 /PRNewswire/ -- KeyBank announces twenty (20) charitable donations made by KeyBank Foundation, the bank's charitable foundation to nonprofit organizations throughout its Hudson Valley/Metro New York market.
"KeyBank's commitment to the communities we serve is at the heart what we stand for," said KeyBank Market President John Manginelli.
"We value the partnerships we have with local nonprofit organizations and are proud to support their important community work."
Bowery Mission, New York, NY to support its Continuum of Care Services for New Yorkers experiencing homelessness, food insecurity and other crises.

Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer

Retrieved on:

Thursday, December 14, 2023

Carboplatin, NCI-designated Cancer Center, Hay, NYSE, Quest Diagnostics, RWJBarnabas Health, National Cancer Institute, Clinical trial, Breast cancer, Patient, Nature, MRD, Prognosis, DGX, MD, Cooper University Hospital, Biology, TNBC, Medical imaging

Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensive Cancer Center.

Key Points:

Rutgers Cancer Institute together with RWJBarnabas Health is the state's only National Cancer Institute-designated Comprehensive Cancer Center.
"We're excited to work with Rutgers Cancer Institute in their efforts to optimize therapeutic strategies for patients with early-stage breast cancer," said Dan Edelstein, Vice President and General Manager of Haystack Oncology.
"With unparalleled sensitivity, Haystack MRD provides a tool for anticipating and evaluating treatment-related benefits to a greater depth than standard clinical and radiographic metrics, making it well-equipped to support clinical studies such as this, which are essential for advancing cancer care."
"Triple-negative breast cancer is a subtype of breast cancer that is aggressive by nature with a complex biology, therefore, the disease tends to have a worse prognosis," said Mridula George, MD , associate program director of Breast Medical Oncology at Rutgers Cancer Institute and principal investigator of the study, which is also open at select RWJBarnabas Health sites across New Jersey.

MB2 Dental Launches Modernized Intranet and App Platform

Retrieved on:

Thursday, November 9, 2023

MB2 Dental , the first and largest dental partnership organization (DPO), announced today the rollout of a groundbreaking intranet platform across its organization of more than 650 affiliated practices nationwide.

Key Points:

MB2 Dental , the first and largest dental partnership organization (DPO), announced today the rollout of a groundbreaking intranet platform across its organization of more than 650 affiliated practices nationwide.
The modernized intranet platform, Cerebro, has streamlined communications for the growing Company.
Cameron Lindsay, CEO and founder of Haystack was thrilled to see MB2 Dental's successful adoption of the innovative intranet tool, “Haystack empowers organizations like MB2 Dental to connect, collaborate and share information seamlessly.
Working with a highly successful organization like MB2 Dental has been an incredibly rewarding experience.”

Jio Harnesses Plume's Cloud Platform to Bring Best-In-Class In-Home Experiences to Consumers in India

Retrieved on:

Wednesday, October 25, 2023

Jio, Wi-Fi, Small business, Hay, Partnership, Video game, Plume

MUMBAI, India, Oct. 25, 2023 /PRNewswire/ -- NETWORK X, Paris -- Reliance Jio Infocomm Limited, India's largest telecom network, today announced a partnership with consumer experience pioneer Plume® to provide market-leading smart home and small business services to its subscribers across India. This partnership will deliver state-of-the-art solutions, through Plume's highly scalable cloud platform, to approximately 200 million premises in India.

Key Points:

This partnership will deliver state-of-the-art solutions, through Plume's highly scalable cloud platform, to approximately 200 million premises in India.
Jio specializes in meeting the digital needs of customers based in India, providing fixed-line and wireless services delivered through the cloud, with all the infrastructure hosted in the country.
"The partnership with Jio marks a significant global expansion of Plume's services with a major telecoms force in Asia.
"We are thrilled to help Jio deliver unique and highly personalized in-home digital experiences to its customers across India and support the company in the next chapter of its growth journey."

Jio Harnesses Plume's Cloud Platform to Bring Best-In-Class In-Home Experiences to Consumers in India

Retrieved on:

Wednesday, October 25, 2023

Jio, Wi-Fi, Small business, Hay, Partnership, Video game, Plume

MUMBAI, India, Oct. 25, 2023 /PRNewswire/ -- NETWORK X, Paris -- Reliance Jio Infocomm Limited, India's largest telecom network, today announced a partnership with consumer experience pioneer Plume® to provide market-leading smart home and small business services to its subscribers across India. This partnership will deliver state-of-the-art solutions, through Plume's highly scalable cloud platform, to approximately 200 million premises in India.

Key Points:

This partnership will deliver state-of-the-art solutions, through Plume's highly scalable cloud platform, to approximately 200 million premises in India.
Jio specializes in meeting the digital needs of customers based in India, providing fixed-line and wireless services delivered through the cloud, with all the infrastructure hosted in the country.
"The partnership with Jio marks a significant global expansion of Plume's services with a major telecoms force in Asia.
"We are thrilled to help Jio deliver unique and highly personalized in-home digital experiences to its customers across India and support the company in the next chapter of its growth journey."